Immunology
An Introduction to Immunology
Stay up to date with the latest clinical breakthroughs and highlights from major global conferences through expert-led conference coverage, concise insights and news articles. Browse premium, actionable practice pearl articles designed to support continuous development, confidence and clinical decision-making. Plus, explore free-to-view, peer-reviewed articles from our leading international journal, alongside high-quality educational activities—with patient outcomes at the forefront.
The FDA has granted accelerated approval to atacicept-vymj in adults with primary immunoglobulin A nephropathy (IgAN). The approval is based on findings from the prespecified 36-week interim analysis of the phase 3 ORIGIN 3 trial (NCT04716231), presented at ASN Kidney Week. Continued approval will be contingent on confirmation of clinical benefit in the ongoing phase 3 study.
The US Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for ravulizumab as a potential treatment for adults with immunoglobulin A nephropathy (IgAN).
Could inhibiting B cells, rather than depleting them, offer a new approach to treating IgG4-related disease? In this interview from EULAR 2026, Dr Emanuel Della Torre discusses the unmet needs in IgG4-RD, the unique mechanism of the investigational therapy obexelimab, and key findings from the phase 3 INDIGO trial.
Meet the immunologists redefining the future of practice, research, and technology! The touchIMMUNOLOGY Future Leaders 2026 have been nominated by the immunology community to recognize the rising stars shaping the future of research and clinical care. These clinicians, researchers and innovators are driving progress across the specialty — from advancing clinical practice to challenging convention and improving patient outcomes.
In this Q&A, 2026 Future Leader Christian Pacher-Deutsch highlights the most significant mentors in his career, a defining breakthrough in his research and how it impacted the field, and the advice he would give to medical students or young professionals considering a career in research.
In this Q&A, touchIMMUNOLOGY Future Leader Dr Diray Arce reflects on what first drew her to systems immunology and vaccinology, the experiences that shaped her path in this field, and the advice she would give to medical students or young professionals considering a similar career.
touchIMMUNOLOGY Future Leader Cedric Bogaert discusses his journey at the intersection of science and technology, from co-founding myNEO Therapeutics to advancing innovation in precision medicine. He reflects on key milestones in his career, the growth of his team, and offers advice for those considering a future in immunology and healthcare innovation.
In this Q&A, touchIMMUNOLOGY Future Leader Dr Luisina Onofrio reflects on what first drew her to translational immunology, the key breakthroughs shaping her research, and the innovations driving the future of autoimmune disease care.
In this Q&A, touchIMMUNOLOGY Future Leader Dr Sadhu reflects on what first drew him to immunology, the defining breakthroughs in his research, and the legacy he hopes to leave in the field of immunology.
We are counting down to the launch of touchIMMUNOLOGY Future Leaders 2026 – a celebration of the rising stars shaping the future of immune-related diseases.
Recent regulatory developments highlight a steady acceleration in therapeutic progress across rare immunological diseases, spanning autoimmune, autoinflammatory and primary immunodeficiency disorders. While individually rare, these conditions collectively represent a growing area of focus, with advances increasingly driven by targeted modulation of specific immune pathways. A series of recent approvals and designations across major regulatory regions underscores both the clinical need and the expanding therapeutic toolkit in this space.
We are delighted to announce that nominations are now open for touchIMMUNOLOGY Future Leaders 2026! Join us to celebrate the future of the field.
As the field of immunology continues to evolve, staying ahead of the curve has never been more critical. As we welcome the new year, we asked our touchIMMUNOLOGY 2025 Future Leaders to share the developments they believe will shape the future of the field. Here, they highlight five emerging areas poised to influence clinical practice—not only in the year ahead, but for years to come.
S3E3_Could senolytics change the treatment landscape of age-related diseases? In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related ...
The liver macrophage niche plays a central role in maintaining hepatic homeostasis and driving responses to injury. Advances in intravital microscopy are providing unprecedented insights into how these cells adapt in both health and disease, opening new avenues for understanding liver pathophysiology. In this Q&A, Dr Moritz Peiseler (Charité Universitätsmedizin Berlin, Berlin, Germany) highlights how intravital microscopy reveals the dynamic, environment-dependent behaviour of liver macrophages, showing early disease-related changes that could guide new diagnostic and therapeutic strategies, while emphasizing the innate immune system’s memory and the potential for future human applications.
As touchIMMUNOLOGY approaches 5 years of providing education for busy healthcare professionals involved with immune-related conditions, we are looking to the future—and it certainly looks bright! This year, we are celebrating our inaugural touchIMMUNOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform the field in the years to come.
July delivered a broad range of important updates in immunology, spanning regulatory approvals, new therapeutic formulations, and key clinical trial results across autoimmune, inflammatory, and rare diseases. This monthly roundup highlights the most significant developments, including first-in-class oral therapies, expanded paediatric indications, and both positive and negative late-phase trial outcomes.
As part of our Future Leader series, we speak with Dr Varol Tunali, a researcher at Ege University Faculty of Medicine, about his pioneering work in parasitology and microbiome science. From investigating the clinical relevance of Blastocystis to exploring the role of AI in personalized medicine, Dr Tunali shares insights into the future of global health, and the values that continue to shape his scientific journey.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
